BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 20220060)

  • 1. Identification of a panel of ten cell surface protein antigens associated with immunotargeting of leukemias and lymphomas by peripheral blood gammadelta T cells.
    Gomes AQ; Correia DV; Grosso AR; Lança T; Ferreira C; Lacerda JF; Barata JT; Silva MG; Silva-Santos B
    Haematologica; 2010 Aug; 95(8):1397-404. PubMed ID: 20220060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comprehensive analysis of primary acute myeloid leukemia identifies biomarkers predicting susceptibility to human allogeneic Vγ9Vδ2 T cells.
    Gundermann S; Klinker E; Kimmel B; Flierl U; Wilhelm M; Einsele H; Kunzmann V
    J Immunother; 2014; 37(6):321-30. PubMed ID: 24911793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The MHC class Ib protein ULBP1 is a nonredundant determinant of leukemia/lymphoma susceptibility to gammadelta T-cell cytotoxicity.
    Lança T; Correia DV; Moita CF; Raquel H; Neves-Costa A; Ferreira C; Ramalho JS; Barata JT; Moita LF; Gomes AQ; Silva-Santos B
    Blood; 2010 Mar; 115(12):2407-11. PubMed ID: 20101024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRTAM receptor engagement by Necl-2 on tumor cells triggers cell death of activated Vγ9Vδ2 T cells.
    Dessarthe B; Thedrez A; Latouche JB; Cabillic F; Drouet A; Daniel P; de La Pintière CT; Catros V; Toutirais O
    J Immunol; 2013 May; 190(9):4868-76. PubMed ID: 23530148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of gammadelta T cells expanded from peripheral blood cells by stimulation with zoledronate.
    Watanabe N; Narita M; Yokoyama A; Sekiguchi A; Saito A; Tochiki N; Furukawa T; Toba K; Aizawa Y; Takahashi M
    Cytotherapy; 2006; 8(2):118-29. PubMed ID: 16698685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthetic phosphoantigens enhance human Vgamma9Vdelta2 T lymphocytes killing of non-Hodgkin's B lymphoma.
    Sicard H; Al Saati T; Delsol G; Fournié JJ
    Mol Med; 2001 Oct; 7(10):711-22. PubMed ID: 11713370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of hematopoietic cell-specific tyrosine phosphatase SHP-1 gene expression in natural killer cell lymphoma and various types of lymphomas/leukemias : combination analysis with cDNA expression array and tissue microarray.
    Oka T; Yoshino T; Hayashi K; Ohara N; Nakanishi T; Yamaai Y; Hiraki A; Sogawa CA; Kondo E; Teramoto N; Takahashi K; Tsuchiyama J; Akagi T
    Am J Pathol; 2001 Oct; 159(4):1495-505. PubMed ID: 11583976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Common features and differences in the transcriptome of large cell anaplastic lymphoma and classical Hodgkin's lymphoma.
    Willenbrock K; Küppers R; Renné C; Brune V; Eckerle S; Weidmann E; Bräuninger A; Hansmann ML
    Haematologica; 2006 May; 91(5):596-604. PubMed ID: 16670065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An abnormal phenotype of lung Vγ9Vδ2 T cells impairs their responsiveness in tuberculosis patients.
    El Daker S; Sacchi A; Montesano C; Altieri AM; Galluccio G; Colizzi V; Martini F; Martino A
    Cell Immunol; 2013 Apr; 282(2):106-12. PubMed ID: 23770719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lineage differentiation of canine lymphoma/leukemias and aberrant expression of CD molecules.
    Wilkerson MJ; Dolce K; Koopman T; Shuman W; Chun R; Garrett L; Barber L; Avery A
    Vet Immunol Immunopathol; 2005 Jul; 106(3-4):179-96. PubMed ID: 15963817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib enhances cytotoxicity of ex vivo-expanded gamma delta T cells against acute myeloid leukemia and T-cell acute lymphoblastic leukemia.
    Story JY; Zoine JT; Burnham RE; Hamilton JAG; Spencer HT; Doering CB; Raikar SS
    Cytotherapy; 2021 Jan; 23(1):12-24. PubMed ID: 33168453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of NKG2D and its ligands in the anti-infectious activity of Vγ9Vδ2 T cells against intracellular bacteria.
    Bessoles S; Ni M; Garcia-Jimenez S; Sanchez F; Lafont V
    Eur J Immunol; 2011 Jun; 41(6):1619-28. PubMed ID: 21469127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of human gamma delta [corrected] T-cell antitumoral activity through HLA-G: implications for immunotherapy of cancer.
    Lesport E; Baudhuin J; Sousa S; LeMaoult J; Zamborlini A; Rouas-Freiss N; Carosella ED; Favier B
    Cell Mol Life Sci; 2011 Oct; 68(20):3385-99. PubMed ID: 21337044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Large-scale expansion of Vγ9Vδ2 T cells with engineered K562 feeder cells in G-Rex vessels and their use as chimeric antigen receptor-modified effector cells.
    Xiao L; Chen C; Li Z; Zhu S; Tay JC; Zhang X; Zha S; Zeng J; Tan WK; Liu X; Chng WJ; Wang S
    Cytotherapy; 2018 Mar; 20(3):420-435. PubMed ID: 29402645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human Vγ9Vδ2 T cells specifically recognize and kill acute myeloid leukemic blasts.
    Gertner-Dardenne J; Castellano R; Mamessier E; Garbit S; Kochbati E; Etienne A; Charbonnier A; Collette Y; Vey N; Olive D
    J Immunol; 2012 May; 188(9):4701-8. PubMed ID: 22467661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antigen-Presenting Cell Characteristics of Human γδ T Lymphocytes in Chronic Myeloid Leukemia.
    Sawaisorn P; Tangchaikeeree T; Chan-On W; Leepiyasakulchai C; Udomsangpetch R; Hongeng S; Jangpatarapongsa K
    Immunol Invest; 2019 Jan; 48(1):11-26. PubMed ID: 30321079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo phosphoantigen levels in bisphosphonate-treated human breast tumors trigger Vγ9Vδ2 T-cell antitumor cytotoxicity through ICAM-1 engagement.
    Benzaïd I; Mönkkönen H; Bonnelye E; Mönkkönen J; Clézardin P
    Clin Cancer Res; 2012 Nov; 18(22):6249-59. PubMed ID: 23032740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased peripheral blood gamma delta T-cells in patients with lymphoid neoplasia: A diagnostic dilemma in flow cytometry.
    McClanahan J; Fukushima PI; Stetler-Stevenson M
    Cytometry; 1999 Dec; 38(6):280-5. PubMed ID: 10589043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysfunctional Vγ9Vδ2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells.
    Coscia M; Vitale C; Peola S; Foglietta M; Rigoni M; Griggio V; Castella B; Angelini D; Chiaretti S; Riganti C; Guarini A; Drandi D; Ladetto M; Bosia A; Foà R; Battistini L; Boccadoro M; Fournié JJ; Massaia M
    Blood; 2012 Oct; 120(16):3271-9. PubMed ID: 22932792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ex vivo characterization of γδ T-cell repertoire in patients after adoptive transfer of Vγ9Vδ2 T cells expressing the interleukin-2 receptor β-chain and the common γ-chain.
    Izumi T; Kondo M; Takahashi T; Fujieda N; Kondo A; Tamura N; Murakawa T; Nakajima J; Matsushita H; Kakimi K
    Cytotherapy; 2013 Apr; 15(4):481-91. PubMed ID: 23391461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.